World

Mpox vaccines to arrive in DR Congo in next few days, WHO says

Aug 31, 2024

Geneva [Switzerland], August 31: The World Health Organisation chief said on Friday that mpox vaccines were set to arrive in the Democratic Republic of Congo in the next few days to fight a new strain of the virus.
"We hope to have the first delivery in the next few days, and then it will build up," Director General Tedros Adhanom Ghebreyesus told reporters at a press conference.
Some 230,000 mpox doses are immediately available to be dispatched, added WHO official Tim Nguyen. These doses were donated by the European Commission and Danish mpox vaccine manufacturer Bavarian Nordic (BAVA.CO), Nguyen said as quoted by Reuters.
The WHO has said that its partners can start buying mpox vaccines before they are approved by the U.N. health agency, lifting its usual rules in a bid to get inoculations to Africa faster.
It is currently reviewing applications for emergency licences for two vaccines made by Bavarian Nordic and Japan's KM Biologics. Tedros said these were expected to be granted in the next two weeks.
Rosamund Lewis, the WHO technical lead for mpox, said she hoped the vaccines and other interventions by health partners would help cases come down again in the near future.
An mpox diagnostic manufacturer also expressed interest in securing WHO's emergency use listing for their kit a day after the agency opened the process, opens new tab, Tedros said without naming the company.
Earlier this month, the WHO declared mpox a global public health emergency following an outbreak of the viral infection in the Democratic Republic of Congo that spread to neighbouring countries. More than 18,000 suspected cases of mpox have been reported in Congo so far this year with 629 deaths, while over 150 cases have also been confirmed in Burundi, Tedros said.
Source: Emirates News Agency

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025